Abstract
Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine with many biological effects on a variety of cells. In particular, TNF-α has been shown to act as a death or survival factor which mediates apoptosis or antiapoptotic signals in various types of cells. In eosinophils, TNF-α has been reported to activate eosinophil functions. However, it is not clearly defined whether TNF-α delivers antiapoptotic signals in eosinophils. In order to determine whether TNF-α prevents eosinophil apoptosis, we examined the effect of TNF-α on eosinophil apoptosis by the survival assay and cell cycle analysis. We also determined whether intracellular MAP kinases (ERKs, Jun kinase/JNK, and p38 MAP kinase) are involved in the TNF-α-induced signaling for the prevention of eosinophil apoptosis. We showed that TNF-α mediated antiapoptotic signals in human eosinophils in part via activation of p38 MAP kinase, but not via activation of ERKs and JNK. Our data suggest that TNF-α/p38 MAP kinase pathways are involved in the regulation of eosinophil survival and, thus, would be important for the development of allergic eosinophil-rich inflammation.
References
1.
Tracey K, Cerami A: Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1993;9:317–343.
2.
Silberstein DS, David JR: Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae. Proc Natl Acad Sci USA 1986;83:1055–1059.
3.
Horie S, Gleich GJ, Kita H: Cytokines directly induce degranulation and superoxide production from human eosinophils. J Allergy Clin Immunol 1996;98:371–381.
4.
Lukacs NW, Strieter RM, Chenusue SW, Widmer M, Kunkel SL: TNF-α mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol 1995;154:5411–5417.
5.
Gleich GJ: The eosinophil and bronchial asthma: Current understanding. J Allergy Clin Immunol 1990;85:422–436.
6.
Cembryznska-Nowak M, Szklarz E, Inglot AD, Teodoczyk-Injeyan JA: Elevated release of tumor necrosis factor-α and interferon-γ by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis 1993;147:291–296.
7.
Simon H-U, Yousefi S, Schranz C, Schapowal A, Bachert C, Blase K: Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997;158:3902–3908.
8.
Van Antwerp DJ, Martin SJ, Verma IM, Green DR: Inhibition of TNF-induced apoptosis by NF-κB. Trends Cell Biol 1998;8:107–111.
9.
Hansel TT, De Vries IJM, Iff T, Rihs S, Wandzilak M, Betz S, Blaser K, Walker C: An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 1991;145:105–110.
10.
Cuend A, Rouse J, Doza YN, Neier R, Cohen P, Gallagher TF, Young RR, Lee JC: SB203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995;364:229–233.
11.
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271–279.
12.
Hiraguri M, Miike S, Sano H, Kurasawa K, Saito Y, Iwamoto I: Granulocyte-macrophage colony-stimulating factor and interleukin-5 activate mitogen-activated protein kinase through Jak2 kinase and phosphatidylinositol 3-kinase in human eosinophils. J Allergy Clin Immunol 1997;100:S45–51.
13.
Simon HU, Yousefi S, Fibbert B, Levi-Schaffer F, Blaser K: Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur J Immunol 1997;27:3536–3539.
14.
Levi-Schaffer F, Temkin V, Malamud V, Feld S, Zilberman Y: Mast cells enhance eosinophil survival in vitro: Role of TNF-α and granulocyte-macrophage colony stimulating factor. J Immunol 1998;160:5554–5562.
15.
Tewari M, Dixit VM: Signaling through members of the tumor necrosis factor receptor family; in Heldin C-H, Purton M (eds): Signal Transduction. London, Chapman & Hall, 1996, pp 79–92.
16.
Liu Z-G, Hsu H, Goeddel DV, Karin M: Dissection of TNF receptor I effector functions: JNK activation it not linked to apoptosis while NF-κB activation prevents cell death. Cell 1996;87:565–576.
17.
Natoli G, Costanzo A, Ianni A, Templeton DJ, Woodgett JR, Balsano C, Levrero M: Activation of SAPK/JNK by TNF receptor I through a noncytotoxic TRAF2-dependent pathway. Science 1997;275:200–203.
18.
Cesaris PD, Starace D, Riccioli A, Padula F, Filippini A, Ziparo E: Tumor necrosis factor-α induces interleukin-6 production and integrin ligand expression by distinct transduction pathways. J Biol Chem 1998;27:7566–7571.
19.
Carpentier I, Declercq W, Malinin NL, Wallach D, Fiers W, Beyaert R: TRAF2 plays a dual role in NF-κB-dependent gene activation by mediating the TNF-induced activation of p38 MAPK and IkB kinase pathways. FEBS Lett 1998;425:195–198.
20.
Nishida E, Gotoh Y: The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 1993;18:128–131.
21.
Roulston A, Reinhard C, Amiri P, Williams LT: Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor-α. J Biol Chem 1998;17:10232–10239.
22.
Beyaert R, Kidd VJ, Cornelis S, Van de Craen M, Denecker G, Lahti JM, Gururajan R, Vandenabeele P, Fiers W: The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 1996;15:1914–1923.
23.
Beg AA, Baltimore D: An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782–784.
24.
Wang C-Y, Mayo MW, Baldwin AS Jr: TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 1996;274:784–787.
25.
Antwerp DJV, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787–789.
26.
Pazdrak K, Olszewska-Pazdrak B, Stafford S, Garofalo RP, Alam R: Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic effect of interleukin-5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation. J Exp Med 1998;188:421–429.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
